Tu banner alternativo

Selurampanel

In this article, we are going to explore the topic of Selurampanel from different perspectives and approaches. Selurampanel is a topic that has captured the attention of experts in the field, as well as the general public, due to its relevance and importance today. Along these lines, we will analyze the different aspects related to Selurampanel, from its history and evolution, to its implications in contemporary society. In order to offer a comprehensive and balanced view, we will also address the controversies and debates that have arisen around this topic, in an attempt to shed light on its different facets. Thus, Selurampanel is revealed as a topic of great relevance and interest, which deserves to be analyzed and understood in depth.

Tu banner alternativo
Selurampanel
Clinical data
ATC code
  • None
Identifiers
  • N-methanesulfonamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H19N5O4S
Molar mass377.42 g·mol−1
3D model (JSmol)
  • CC(C)c1cc2c(cc1c3ccnn3C)c(=O)n(c(=O)2)NS(=O)(=O)C
  • InChI=1S/C16H19N5O4S/c1-9(2)10-8-13-12(7-11(10)14-5-6-17-20(14)3)15(22)21(16(23)18-13)19-26(4,24)25/h5-9,19H,1-4H3,(H,18,23)
  • Key:MCECSFFXUPEPDB-UHFFFAOYSA-N

Selurampanel (INN, code name BGG492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy.[1][2][3] It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.[4]

References

  1. ^ Faught E (January 2014). "BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy". Expert Opinion on Investigational Drugs. 23 (1): 107–113. doi:10.1517/13543784.2014.848854. PMID 24147649. S2CID 40105670.
  2. ^ Belcastro V, Verrotti A (2015). "Novel Molecular Targets for Drug-Treatment of Epilepsy". In Striano P (ed.). Epilepsy Towards the Next Decade. Contemporary Clinical Neuroscience. pp. 183–199. doi:10.1007/978-3-319-12283-0_10. ISBN 978-3-319-12282-3.
  3. ^ Hanada T (2014). "The AMPA receptor as a therapeutic target in epilepsy: preclinical and clinical evidence". Journal of Receptor, Ligand and Channel Research: 39. doi:10.2147/JRLCR.S51475. ISSN 1178-699X.
  4. ^ Gomez-Mancilla B, Brand R, Jürgens TP, Göbel H, Sommer C, Straube A, et al. (February 2014). "Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks". Cephalalgia. 34 (2): 103–113. doi:10.1177/0333102413499648. PMID 23963355. S2CID 206520491.
Stub icon

This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia